Current Use of Immunosuppression in Liver Transplantation.
Antibody-mediated rejection
Immunosuppression
Induction immunosuppression
Liver transplant
Journal
The Surgical clinics of North America
ISSN: 1558-3171
Titre abrégé: Surg Clin North Am
Pays: United States
ID NLM: 0074243
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
medline:
14
11
2023
pubmed:
13
11
2023
entrez:
12
11
2023
Statut:
ppublish
Résumé
Since the first successful liver transplant in 1967, immunosuppression has allowed liver transplantation to become the standard treatment of end-stage liver disease. Over the decades, the rates of rejection have decreased, and patient survival outcomes have significantly improved in large part due to the introduction and advancements of immunosuppression medications. However, the adverse effects associated with long-term immunosuppression have created new challenges facing liver transplantation and added significantly to posttransplantation morbidity. This review presents the data and rationale for immunosuppression approaches, addresses the main controversies related to immunosuppression in liver transplantation, and explores some of the newer advancements in immunosuppressive drug therapy.
Identifiants
pubmed: 37953030
pii: S0039-6109(23)00138-X
doi: 10.1016/j.suc.2023.08.004
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-25Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.